Shares of Limerick, PA-based specialty medical devices
) reached new 52-week high of $106.70 in mid-day trading
yesterday following the announcement of study results favoring
the use of the company's ARROW Central Venous Catheter (CVC) with
ARROWg+ard Blue PLUS Technology. Shares of the company closed at
$106.10 on the same day, representing a solid one-year return of
ABIOMED INC (ABMD): Free Stock Analysis
CYNOSURE INC-A (CYNO): Free Stock Analysis
SYNERON MED LTD (ELOS): Free Stock Analysis
TELEFLEX INC (TFX): Free Stock Analysis
To read this article on Zacks.com click here.
The study, conducted by Leonardo Lorente M.D., Ph.D. and his
colleagues independently, found that the Teleflex's ARROW
catheter with ARROWg+ard Blue PLUS Technology lowers the risk of
catheter-related bloodstream infections (CRBSIs) and decreases
direct treatment costs of these fatal infections.
Lorente and his fellow colleagues compared the antimicrobial
protected ARRROW catheter with an unprotected CVC. They found
that the cost per catheter day of the protected catheter was
about half that of the unprotected catheter.
Moreover, the ARROWg+ard Blue PLUS catheter achieved zero
infections in the study. In contrast, the unprotected catheters
were associated with infections in 2% of cases.
The study included the costs of CVCs, infection diagnosis, and
antimicrobials used to treat patients who suffered infections. It
has involved patients admitted in ICU of the Hospital
Universitario de Canarias in Tenerife, Spain.
The patients received one or more internal jugular venous
catheters. The study examined a total of 636 catheters and 3,271
Shares of Teleflex started escalating following its impressive
2013-fourth quarter results and promising 2014 guidance on Feb
21. The company posted an 18.3% rise in adjusted earnings to
$1.36 per share for the fourth quarter of 2013 from $1.15 in the
same quarter of 2012. With this, earnings significantly beat the
Zacks Consensus Estimate by 9 cents.
Net revenues went up 7.5% to $450.5 million, exceeding the Zacks
Consensus Estimate of $436 million. Excluding foreign exchange
fluctuations, net revenues rose 6.9% from the prior-year quarter.
The increase in revenues was attributable to contribution from
the acquisitions of LMA International in Oct 2012 and Vidacare
Corporation in Dec 2013, an increase in the average selling price
of products, launch of new products and an additional shipping
day in the reported quarter versus the same quarter of 2012.
For 2014, Teleflex anticipates revenue growth between 6.0 and
8.0% versus 2013. In constant currency, the company expects
revenues to increase by 7.0 and 9.0%.
Teleflex also expects adjusted earnings per share in the range of
$5.35 to $5.55 for 2014, reflecting a 6.4 to 10.3% rise from
2013. The current Zacks Consensus Estimate of $5.52 lies at the
upper end of the guided range.
Currently, Teleflex carries a Zacks Rank #2 (Buy). Other players
in the medical instruments industry that also worth a look
Syneron Medical Ltd.
). Both Cynosure and Syneron Medical sport a Zacks Rank #1
(Strong Buy), while ABIOMED carries a Zacks Rank #2 (Buy).